Lineage Cell Therapeutics (LCTX) CEO receives 3.25M stock option grant

Rhea-AI Filing Summary

Lineage Cell Therapeutics reported that its President and CEO, Brian M. Culley, received a grant of stock options covering 3,250,000 shares of common stock. The options have an exercise price of $0.00 per share, reflecting a compensatory award rather than a market purchase.

According to the terms, one quarter of these options will vest on March 5, 2027, and the remaining options will vest in 36 monthly installments thereafter, contingent on continued employment. Following this award, Culley holds 3,250,000 stock options directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Culley Brian M

(Last) (First) (Middle)

C/O LINEAGE CELL THERAPEUTICS

2173 SALK AVENUE, SUITE 200

(Street)

CARLSBAD CA 92008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lineage Cell Therapeutics, Inc. [ LCTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$1.84	03/05/2026		A		3,250,000		(1)	03/05/2036	Common Shares	3,250,000	$0	3,250,000	D

Explanation of Responses:

1. One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.

	/s/ Brian M. Culley	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lineage Cell Therapeutics (LCTX) report for Brian M. Culley?

Lineage Cell Therapeutics reported that President and CEO Brian M. Culley received a grant of 3,250,000 employee stock options. These options are a compensatory award with a $0.00 exercise price per share, increasing his direct option holdings to 3,250,000.

What are the vesting terms of Brian M. Culley’s new stock options at Lineage Cell Therapeutics (LCTX)?

The options granted to Brian M. Culley vest over time. One quarter of the 3,250,000 options will vest on March 5, 2027, and the remaining balance vests in 36 equal monthly installments, subject to his continuous employment with the company.

Is Brian M. Culley’s Form 4 transaction in LCTX shares a purchase or a grant?

The Form 4 transaction for Brian M. Culley reflects a grant of employee stock options, not an open-market share purchase. It is coded as a grant, award, or other acquisition, providing rights to buy shares under specified vesting conditions.

How many Lineage Cell Therapeutics (LCTX) options does Brian M. Culley hold after this Form 4 filing?

After the reported grant, Brian M. Culley directly holds 3,250,000 employee stock options. This total reflects the full amount from the new award, which will vest over several years based on his continued employment with Lineage Cell Therapeutics.

What does the $0.00 exercise price mean for Brian M. Culley’s LCTX stock options?

The $0.00 exercise price indicates these options are structured as a compensatory right rather than a typical market-priced option. It gives Culley the right to acquire shares without paying an exercise price, subject to the vesting schedule and continued employment requirements.